MX2022015737A - Compuestos para mejorar el empalme del acido ribonucleico mensajero (arnm). - Google Patents

Compuestos para mejorar el empalme del acido ribonucleico mensajero (arnm).

Info

Publication number
MX2022015737A
MX2022015737A MX2022015737A MX2022015737A MX2022015737A MX 2022015737 A MX2022015737 A MX 2022015737A MX 2022015737 A MX2022015737 A MX 2022015737A MX 2022015737 A MX2022015737 A MX 2022015737A MX 2022015737 A MX2022015737 A MX 2022015737A
Authority
MX
Mexico
Prior art keywords
compounds
mrna splicing
improving mrna
improving
methods
Prior art date
Application number
MX2022015737A
Other languages
English (en)
Inventor
Juan MARUGAN
Graham Johnson
Susan A Slaugenhaupt
William D Paquette
Wei Zhang
Original Assignee
Massachusetts Gen Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Gen Hospital filed Critical Massachusetts Gen Hospital
Publication of MX2022015737A publication Critical patent/MX2022015737A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Se proveen compuestos útiles para mejorar el empalme del ARNm en una célula. Los compuestos ejemplares provistos en la presente son útiles para mejorar el empalme de ARNm en genes que comprenden por lo menos un exón que termina en la secuencia de nucleótidos CAA. También se proveen métodos para preparar los compuestos y métodos de tratamiento de enfermedades del sistema nervioso central.
MX2022015737A 2015-01-16 2017-07-14 Compuestos para mejorar el empalme del acido ribonucleico mensajero (arnm). MX2022015737A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562104547P 2015-01-16 2015-01-16
US201562180380P 2015-06-16 2015-06-16

Publications (1)

Publication Number Publication Date
MX2022015737A true MX2022015737A (es) 2023-01-18

Family

ID=56406434

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017009295A MX2017009295A (es) 2015-01-16 2016-01-15 Compuestos para mejorar el empalme del acido ribonucleico mensajero (arnm).
MX2022015737A MX2022015737A (es) 2015-01-16 2017-07-14 Compuestos para mejorar el empalme del acido ribonucleico mensajero (arnm).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017009295A MX2017009295A (es) 2015-01-16 2016-01-15 Compuestos para mejorar el empalme del acido ribonucleico mensajero (arnm).

Country Status (16)

Country Link
US (3) US10676475B2 (es)
EP (2) EP4115882A1 (es)
AU (2) AU2016206589B2 (es)
BR (1) BR112017015019A2 (es)
CA (2) CA3199430A1 (es)
CL (2) CL2017001823A1 (es)
DK (1) DK3244891T3 (es)
EA (1) EA037663B1 (es)
ES (1) ES2928714T3 (es)
HU (1) HUE059891T2 (es)
IL (2) IL253291B (es)
MX (2) MX2017009295A (es)
PL (1) PL3244891T3 (es)
PT (1) PT3244891T (es)
TW (2) TW202204345A (es)
WO (1) WO2016115434A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3244891T3 (pl) * 2015-01-16 2022-12-27 The General Hospital Corporation Związki poprawiające splicing mRNA
CN110946865B (zh) 2015-12-10 2024-01-26 Ptc医疗公司 用于治疗亨廷顿病的方法
AU2017345736B2 (en) 2016-10-21 2022-04-07 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
CN114432318A (zh) * 2017-02-20 2022-05-06 国立大学法人京都大学 用于起因于剪接异常的遗传性疾病的药物组合物及治疗方法
EP3634953B1 (en) 2017-06-05 2024-01-03 PTC Therapeutics, Inc. Compounds for treating huntington's disease
MX2019015578A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
CN111163838B (zh) 2017-06-28 2023-03-28 Ptc医疗公司 用于治疗亨廷顿氏病的方法
JP7399870B2 (ja) 2018-03-27 2023-12-18 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
PL3814357T3 (pl) 2018-06-27 2024-09-16 Ptc Therapeutics, Inc. Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona
KR20210038845A (ko) 2018-06-27 2021-04-08 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로아릴 화합물
KR102903997B1 (ko) * 2018-10-01 2025-12-26 젠자임 코포레이션 UDP 글리코실트랜스퍼라제 억제제로서의 티에노[3,2-b]피리딘 유도체 및 사용 방법
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia
CA3129067A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
KR20210146287A (ko) * 2019-03-01 2021-12-03 레볼루션 메디슨즈, 인크. 이환식 헤테로아릴 화합물 및 이의 용도
CN113727758A (zh) * 2019-03-01 2021-11-30 锐新医药公司 双环杂环基化合物及其用途
CN114245794B (zh) 2019-05-13 2024-09-13 Ptc医疗公司 用于治疗亨廷顿氏病的化合物
BR112022008858A2 (pt) 2019-11-08 2022-09-06 Revolution Medicines Inc Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
WO2021118929A1 (en) * 2019-12-12 2021-06-17 Ptc Therapeutics, Inc. Compounds for treating familial dysautonomia
EP4084796A1 (en) 2020-01-02 2022-11-09 The General Hospital Corporation Rna splicing modulation
CN111777612B (zh) * 2020-06-05 2022-04-19 广东达元绿洲食品安全科技股份有限公司 一种6-苄基腺嘌呤半抗原、人工抗原及其在免疫检测中的应用
EP4288441A4 (en) * 2021-02-05 2024-12-11 PTC Therapeutics, Inc. Methods for treating spinocerebellar ataxia type 3
CN113151296B (zh) * 2021-03-22 2022-09-13 云南中烟工业有限责任公司 一种烟草热激蛋白相关的基因及其应用
JP2024533323A (ja) 2021-09-07 2024-09-12 ピーティーシー セラピューティクス， インコーポレイテッド 神経変性疾患を処置するための方法
CA3230996A1 (en) 2021-09-07 2023-03-16 Ptc Therapeutics, Inc. Methods for treating neurogenerative diseases
WO2025227159A1 (en) * 2024-04-26 2025-10-30 The General Hospital Corporation Gene editing treatment for correcting splicing defect in familial dysautonomia

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3041340A (en) 1962-06-26 Method of preparing substituted
US3037980A (en) 1955-08-18 1962-06-05 Burroughs Wellcome Co Pyrrolopyrimidine vasodilators and method of making them
GB9613736D0 (en) 1996-07-01 1996-09-04 Hancock Tony Transport cradle for a skid-supported helicopter
US6933280B2 (en) * 1996-10-08 2005-08-23 Gerardo Castillo Peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders
WO1999043676A2 (en) 1998-02-26 1999-09-02 Aventis Pharmaceuticals Inc. 6,9-disubstituted 2-[trans-(4- aminocyclohexyl) amino]purines
CZ294535B6 (cs) 2001-08-02 2005-01-12 Ústav Experimentální Botaniky Avčr Heterocyklické sloučeniny na bázi N6-substituovaného adeninu, způsoby jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující
AU2003304276A1 (en) 2002-09-10 2005-01-21 The Regents Of The University Of California Methods and devices for determining a cell characteristic, and applications employing same
AU2004278773B2 (en) 2003-10-03 2011-05-19 The General Hospital Corporation Methods for altering mRNA splicing and treating familial dysautonomia and other mechanistically related disorders
US20050239806A1 (en) * 2004-01-13 2005-10-27 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
GB0526246D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
CN106008512B (zh) * 2006-02-02 2019-03-12 千禧药品公司 E1活化酶抑制剂
EP1889847A1 (en) * 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
AU2008231304B2 (en) * 2007-03-23 2011-05-12 Amgen Inc. Heterocyclic compounds and their uses
GB0706632D0 (en) 2007-04-04 2007-05-16 Cyclacel Ltd New purine derivatives
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
JP2011518219A (ja) * 2008-04-22 2011-06-23 ポートラ ファーマシューティカルズ， インコーポレイテッド タンパク質キナーゼの阻害剤
JP2012504157A (ja) 2008-09-30 2012-02-16 アストラゼネカ アクチボラグ 複素環式ｊａｋキナーゼ阻害剤
CA2748943A1 (en) * 2009-02-09 2010-08-12 Supergen, Inc. Pyrrolopyrimidinyl axl kinase inhibitors
WO2010118367A2 (en) 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
WO2011041655A1 (en) 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Quinazolin-4-amine derivatives; and methods of use
JP2011136925A (ja) * 2009-12-28 2011-07-14 Dainippon Sumitomo Pharma Co Ltd 含窒素二環性化合物
US20130072506A1 (en) 2011-09-16 2013-03-21 Lenka ZAHAJSKA 6,8-disubstituted purine compositions
BR112014011875B1 (pt) * 2011-11-18 2022-01-04 Sarepta Therapeutics, Inc Oligonucleotídeos funcionalmente modificados e subunidades dos mesmos
CZ306894B6 (cs) 2013-02-08 2017-08-30 Univerzita PalackĂ©ho v Olomouci 2-Substituované-6-biarylmethylamino-9-cyklopentyl-9H-purinové deriváty, jejich použití jako léčiva a farmaceutické přípravky tyto sloučeniny obsahující
WO2014124458A1 (en) 2013-02-11 2014-08-14 The Regents Of The University Of California Compositions and methods for treating neurodegenerative diseases
US9938279B2 (en) 2013-04-09 2018-04-10 Energenesis Biomedical Co., Ltd Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK)
WO2015005491A1 (ja) 2013-07-12 2015-01-15 国立大学法人京都大学 疾病の発症又は進行の一因となる異常スプライシングを抑制できる物質のスクリーニング方法
US10167286B2 (en) 2014-02-11 2019-01-01 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
WO2016011394A1 (en) 2014-07-18 2016-01-21 The General Hospital Corporation Imaging agents for neural flux
PL3244891T3 (pl) * 2015-01-16 2022-12-27 The General Hospital Corporation Związki poprawiające splicing mRNA

Also Published As

Publication number Publication date
EP3244891B9 (en) 2022-11-16
IL253291A0 (en) 2017-09-28
HUE059891T2 (hu) 2023-01-28
ES2928714T3 (es) 2022-11-22
IL253291B (en) 2021-10-31
MX2017009295A (es) 2018-03-07
IL270945A (en) 2020-01-30
CA2973949A1 (en) 2016-07-21
CL2017001823A1 (es) 2018-04-13
ES2928714T9 (es) 2022-11-29
CA3199430A1 (en) 2016-07-21
AU2016206589B2 (en) 2020-09-10
EA201791624A1 (ru) 2018-06-29
EA037663B1 (ru) 2021-04-28
PT3244891T (pt) 2022-10-20
TWI727939B (zh) 2021-05-21
US10676475B2 (en) 2020-06-09
CL2019002167A1 (es) 2019-12-13
TW202204345A (zh) 2022-02-01
EP3244891A4 (en) 2018-12-19
US11702417B2 (en) 2023-07-18
TW201636341A (zh) 2016-10-16
AU2020277224A1 (en) 2020-12-24
DK3244891T3 (da) 2022-10-24
US20200283441A1 (en) 2020-09-10
AU2016206589A1 (en) 2017-07-27
US20180118748A1 (en) 2018-05-03
AU2020277224B2 (en) 2022-12-22
EP3244891B1 (en) 2022-07-20
BR112017015019A2 (pt) 2018-01-30
PL3244891T3 (pl) 2022-12-27
US20230279007A1 (en) 2023-09-07
CA2973949C (en) 2023-07-11
EP3244891A1 (en) 2017-11-22
EP4115882A1 (en) 2023-01-11
WO2016115434A1 (en) 2016-07-21

Similar Documents

Publication Publication Date Title
MX2022015737A (es) Compuestos para mejorar el empalme del acido ribonucleico mensajero (arnm).
IL287889A (en) Administration of engineered t cells for treatment of cancers in the central nervous system
IL286868A (en) Compounds and methods that monitor the expression of genes in the central nervous system
IL260959A (en) Gene therapy for the treatment of mucoid polysaccharomyces type i
GB2593353B (en) Methods for targeted insertion of DNA in genes
IL262361B1 (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
IL262304A (en) Methods for providing single-stranded rna
IL251896A0 (en) A method for enriching cancerous DNA in the bloodstream
SG11202007140XA (en) Bioprocessing methods for cell therapy
IL265953A (en) Gene insertion is targeted for improved immune cell therapy
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
IL257486A (en) Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder
EA201891192A1 (ru) Средства и способы лечения миопатий, связанных с титином, и других титинопатий
EP3110974A4 (en) Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
TW201613975A (en) Methods for treating multiple myeloma
EP3321354A4 (en) Method for inducing oligodendrocyte precursor cells from oct4-induced human somatic cells through direct reprogramming
EP3283502A4 (en) METHOD FOR REACTIVATING GENES ON THE INACTIVE X-CHROMOSOME
EP3551750A4 (en) GENE THERAPY TO TREAT MUCOPOLYSACCHARIDOSIS TYPE I
MX390143B (es) Secuencias recombinantes de cromosoma b de maíz y sus usos
MX2018005872A (es) Profarmacos de acido nucleico.
EP3159403A4 (en) Method for preparing dendritic cells with increased specific gene expression, and composition for treating or preventing autoimmune diseases, containing dendritic cells prepared using same
IL279257A (en) A method for increasing glucose levels in the central nervous system
SG11202106810UA (en) Methods for targeted complementary dna enrichment
IL267231A (en) Methods of treating diseases associated with ilc2 cells
EA202190500A2 (ru) СОЕДИНЕНИЯ ДЛЯ УЛУЧШЕНИЯ СПЛАЙСИНГА мРНК